Cisatracurium Besylate Injection
Product Images NDC 70436-112

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Cisatracurium Besylate (NDC 70436-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Slate Run Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

This text likely refers to a change of 60% over 4 hours and represents variations around 60%. It may be showing a percentage increase or decrease over a specific timeframe.*

FDA Label Image

Figure 2 (Image 02)

FDA Label Image

10 mg Per 5 mL Vial (Image 03)

FDA Label Image

200 mg Per 20 mL (Image 04)

This is a description for a pharmaceutical product labeled as NDC70436-11450, which is Cisatracurium Besylate Injection, USP. It is a paralyzing agent for intravenous use and each mL contains Cisatracurium 10mg equivalent to 13.3 mg of cisatracurium besylate. The warning mentions the potential paralysis of the respiratory system, requiring immediate availability of facilities for artificial respiration. The product should be stored at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) in the carton and used within 21 days once removed from refrigeration. Manufactured by Hainan Poly Pharmaceutical Co. and distributed by SilTé Pharmaceutic,LLC in Columbus, Ohio.*

FDA Label Image

Chemical Structure (Image Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.